These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18778769)

  • 1. Hepatocellular carcinoma and the ubiquitin-proteasome system.
    Dawson SP
    Biochim Biophys Acta; 2008 Dec; 1782(12):775-84. PubMed ID: 18778769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy.
    Chen YJ; Wu H; Shen XZ
    Cancer Lett; 2016 Sep; 379(2):245-52. PubMed ID: 26193663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition.
    Shin DH; Li SH; Chun YS; Huang LE; Kim MS; Park JW
    Oncogene; 2008 Mar; 27(13):1939-44. PubMed ID: 17906695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.
    Mansour MA; Aljoufi MA; Al-Hosaini K; Al-Rikabi AC; Nagi MN
    Chem Biol Interact; 2014 May; 215():17-24. PubMed ID: 24632418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
    Yin J; Zhu JM; Shen XZ
    Int J Cancer; 2015 Jan; 136(2):249-57. PubMed ID: 24420637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ubiquitin-proteasome system in colorectal cancer.
    Voutsadakis IA
    Biochim Biophys Acta; 2008 Dec; 1782(12):800-8. PubMed ID: 18619533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for hepatocellular carcinoma.
    Roberts LR; Gores GJ
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):469-87. PubMed ID: 16939386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin enhances proteasome-mediated generation of the proapoptotic processed form of MAGE-A4 in hepatoma cells.
    Sakurai T; Kudo M; Itoh K; Ryu U; Higashitsuji H; Fujita J
    Oncology; 2011; 81 Suppl 1():30-5. PubMed ID: 22212933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.
    Chen D; Dou QP
    Curr Protein Pept Sci; 2010 Sep; 11(6):459-70. PubMed ID: 20491623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the ubiquitin proteasome system in lymphoma.
    Suh KS; Tanaka T; Sarojini S; Nightingale G; Gharbaran R; Pecora A; Goy A
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):306-22. PubMed ID: 23541070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
    Landis-Piwowar KR
    Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma.
    Altundag O; Altundag K; Turen S; Gunduz E; Atik MA
    Med Hypotheses; 2006; 66(6):1257. PubMed ID: 16154711
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
    Allende-Vega N; Saville MK
    Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia suppresses chemotherapeutic drug-induced p53 Serine 46 phosphorylation by triggering HIPK2 degradation.
    Moehlenbrink J; Bitomsky N; Hofmann TG
    Cancer Lett; 2010 Jun; 292(1):119-24. PubMed ID: 20018442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
    Gong J; Chuang J; Cho M; Toomey K; Hendifar A; Li D
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR; Ovaa H
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.